Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938014 | 0.89 | ALDH1A1 (0.40) | CA6CA5ACA9CA14CA5B | |
| SCHEMBL30221923 | 0.89 | ALDH1A1 (0.40) | CA6CA5ACA9CA14CA5B | |
| SCHEMBL12021951 | 0.83 | ALDH1A1 (0.41) | CA6CA5ACA9CA14CA5B | |
| SCHEMBL5513421 | 0.82 | CA9 (0.53) | CA6CA5ACA9CA14CA5B | |
| SCHEMBL1099578 | 0.82 | ALDH1A1 (0.53) | CA6CA5ACA9CA14CA5B | |
| SCHEMBL932471 | 0.80 | ALDH1A1 (0.42) | CA6CA5ACA9CA14CA5B | |
| SCHEMBL13331358 | 0.77 | ALDH1A1 (0.36) | CA6CA5ACA9CA14CA5B | |
| SCHEMBL16904519 | 0.77 | CYP3A4 (0.46) | CA6CA5ACA9CA14CA5B | |
| SCHEMBL4034317 | 0.77 | HSD17B10 (0.46) | CA6CA5ACA9CA14CA5B | |
| SCHEMBL4843454 | 0.77 | GAA (0.50) | CA6CA5ACA9CA14CA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139795-A1 | Preparation of halogenated 4-aminophenols | LANXESS DEUTSCHLAND GMBH (DE) | 2008-06-12 | — | — | US | claimed |
| US-7358397-B2 | Preparation of halogenated 4-aminophenols | LANXESS DEUTSCHLAND GMBH (DE) | 2008-04-15 | — | — | US | claimed |
| US-20050143425-A1 | Preparation of halogenated 4-aminophenols | LANXESS DEUTSCHLAND GMBH (DE) | 2005-06-30 | — | — | US | claimed |
| EP-1514865-A1 | Process for the preparation of halogen containing 4-amino phenols | Bayer Chemicals AG (DE) | 2005-03-16 | — | — | EP | claimed |
| EP-4673447-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | Boehringer Ingelheim International GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-12479850-B2 | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-25 | — | — | US | disclosed |
| WO-2025072673-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS IRE 1 INHIBITORS | AL22.02.01, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240327429-A1 | [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4 | BOEHRINGER INGELHEIM INT (DE) | 2024-10-03 | — | — | US | disclosed |
| WO-2024180018-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-09-06 | — | — | WO | disclosed |
| CN-116283916-B | Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof | 中国科学院上海药物研究所 | 2024-06-11 | — | — | CN | disclosed |
| CN-117486860-A | Axl & c-Met dual inhibitor, preparation method and application | 上海博悦生物科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024022095-A1 | AXL＆C-MET DUAL INHIBITOR, AND PREPARATION METHOD AND USE | 上海博悦生物科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| US-20050143425-A1 | Preparation of halogenated 4-aminophenols | LANXESS DEUTSCHLAND GMBH (DE) | 2005-06-30 | — | — | US | disclosed |
| CN-1616412-A | Process for the preparation of halogen containing 4-amino phenols | BAYER CHEMICALS AG (DE) | 2005-05-18 | — | — | CN | disclosed |
| EP-1514865-A1 | Process for the preparation of halogen containing 4-amino phenols | Bayer Chemicals AG (DE) | 2005-03-16 | — | — | EP | disclosed |
| EP-1514865-A1 | Process for the preparation of halogen containing 4-amino phenols | Bayer Chemicals AG (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2004078748-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | CCNC, UACA, SLC14A1 | CA6 3240/4885CA5A 1214/4885CA9 3120/4885 |
| US-20240327429-A1 | [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4 | NOX4, NOX1, NOX5 | CA6 4374/4885CA5A 487/4885CA9 4667/4885 |
| US-20080139795-A1 | Preparation of halogenated 4-aminophenols | CYP4X1, CYP4B1, PAH | CA6 3175/4885CA5A 3167/4885CA9 3160/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | CA6 2908/4885CA5A 2177/4885CA9 2863/4885 |
| US-20050143425-A1 | Preparation of halogenated 4-aminophenols | CYP4X1, HPD, CYP4F8 | CA6 3299/4885CA5A 2968/4885CA9 2664/4885 |
| US-12479850-B2 | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof | MET, MERTK, AXL | CA6 2909/4885CA5A 3881/4885CA9 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.